Skip to content

NewAmsterdam Pharma Company NAMS Gain/Loss on Asset Sales

Gain/Loss on Asset Sales at other companies

MYR Group logo
MYR GroupMYRG
$922K-16.3%
SSR Mining logo
SSR MiningSSRM
-$3.24M
NNN REIT logo
NNN REITNNN
$12.19M+220%
Repligen logo
RepligenRGEN
-$13.76M
Unifirst logo
UnifirstUNF
-$233K-3,983%
ST
Sensata TechnologiesST
$0+100%

Other financials

Income statement

See full
Revenue$3.0M+2.1%
Operating income-$58.4M+15.2%
Net income-$48.4M-22.6%
EPS (diluted)-$0.40-17.6%

Balance sheet

See full
Cash & equivalents$457.6M-38.9%
Total debt$23.0K-94.1%
Total equity$665.2M-14.4%
Total assets$732.6M-10.5%

Cash flow

See full
Operating cash flow-$30.6M+16.1%
CapEx$38.0K+138%
Free cash flow-$30.6M+16.0%

Valuation

See full
Market cap$3.67B+63.7%

Profitability

See full
Operating margin-953.6%-3,536pp
Net margin-942.8%-3,477pp
FCF margin-630.1%-6,324pp

Returns & leverage

See full
Return on equity-29.5%-1.8pp
Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's gain/loss on asset sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NewAmsterdam Pharma Company's gain/loss on asset sales?
NewAmsterdam Pharma Company (NAMS) reported gain/loss on asset sales of -$12K in Q1 2026.
What does gain/loss on asset sales mean?
Gains or losses on asset disposals removed from operating cash flow — the cash impact is captured in investing activities.